AQST

Aquestive Therapeutics, Inc.

NasdaqAdd to watchlist

Healthcare · Drug Manufacturers—Specialty & Generic

$4.61

−$0.05−1.07%

Delayed · 2026-09-18T20:00:00.000Z · marketstack

13 of 20 open-market sales on file ran under a pre-arranged trading plan ($1.94M), 7 did not. Who, and when

Aug 24, 2026$4.61

−$0.19−3.96%over 1M

Session

Day range71% of range

$4.51$4.65

Fundamentals

Visualize fundamentals and more

Market cap: 576.22M
P/E ratio: -

Revenue grew −22.61% in FY2025, +31.48% slower than its sector. The median across Healthcare companies this platform tracks is +8.87%.

Risk factors, year on year

Item 1AMar 2026 10-KMar 2025

added: 78
dropped: 108
re-drafted: 50

Out of 262 passages in this year’s Item 1A.

New this year

2024 Underwritten Public Offering Capital raise of gross proceeds of $77,519, including partial exercise of the underwriters' option for $2,519

185 more passages are on Bespoke

Bespoke Create a free account

Free, no card, and it does not expire. See what the paid plans add

What it says it is exposed to

From Item 1A of its most recent 10-K, filed March 2026.

FDA approval
Reimbursement
Litigation
China
Tariffs
Going concern
Inflation
Product recalls

And 15 more.

FDA approval
Union Exchange Act Securities Exchange Act of 1934 Existing Warrants Common Stock Purchase Warrants with the holder of the remaining 5,000,000 warrants FASB Financial Accounting Standards Board FDA U.S.

7 more themes are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

Recent activity

Sep 15 Barber Daniel sold 25,000 shares Insider trading Form 4 President and CEO, about $120k, planned (10b5-1)
Sep 9 Korczynski Sherry sold 8,750 shares Insider trading Form 4 Chief Commercial Officer, about $46k, planned (10b5-1)
Aug 11 Results announcement Company filing 8-K

Discussion

No comments yet

Set a username to join the discussion. It’s the only thing shown next to what you post, never your email address.

Comments are written by other users. Nothing here is investment advice and nothing is checked for accuracy.

Updated Sep 18, 2026 · the last close

Aquestive Therapeutics, Inc. investor relations

What AQST has filed with the SEC. This is not Aquestive Therapeutics, Inc.’s own investor relations site: these filings are the primary source that site publishes from.

Companies like Aquestive Therapeutics, Inc.

Also filed under Drug Manufacturers, ranked by how closely they sit beside AQST.

LLYELI LILLY & Cocompare with AQST
JNJJohnson & Johnsoncompare with AQST
AMGNAmgen Inc.

What it says it is exposed to

From Item 1A of its most recent 10-K, filed March 2026.

FDA approval
Reimbursement
Litigation
China
Tariffs
Going concern
Inflation
Product recalls

And 15 more.

FDA approval
Union Exchange Act Securities Exchange Act of 1934 Existing Warrants Common Stock Purchase Warrants with the holder of the remaining 5,000,000 warrants FASB Financial Accounting Standards Board FDA U.S.

7 more themes are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

MRKMerck & Co., Inc.compare with AQST

BMYBristol Myers Squibb Co.compare with AQST

Ask about Aquestive Therapeutics, Inc.

The assistant answers from what AQST has actually filed: 9 annual reports filed with the SEC, 48 Form 4 filings from the last year and 2 funds that hold it. Every figure in a reply links to the filing it came from, so an answer can be checked rather than believed.

Press one and the answer appears right here on the page, from AQST's filings and figures. One a day without an account; a free account has its own, and no card.

See how much of Aquestive Therapeutics, Inc. each of these investors holds, and every quarter they moved.

Ten seconds. No card. Nothing to cancel.

No card, no broker connection.

Continue with Google

What an account lets you do with Aquestive Therapeutics, Inc.

Be told the moment a AQST insider trades
Put Aquestive Therapeutics, Inc. on a watchlist for a free alert, the bell and a daily email, when a Form 4 worth a row is filed, with vesting and automatic tax sales already struck out so what lands is a decision, not paperwork.
The full filing historyMeasure
Ask what growth the price is already betting on
Aquestive Therapeutics, Inc.'s income statement, balance sheet and cash flow as filed, and the ratios computed from them, plus a reverse DCF that holds today's price fixed and solves for the growth it requires.
The reverse DCFMeasure
Watch the same stakes the professionals are watching
Every tracked position priced at the quarter it was filed and diffed against the one before it: how big a bet each one is, and by how much it changed.
Every position, sizedMeasure
Interrogate the filing, not the internet
Ask anything about Aquestive Therapeutics, Inc.'s fundamentals. The assistant answers from its own filings and cites the figure, never a guess from the open web.

Create a free account See what the paid plans add

Free, no card, and it does not expire.

Recent activity

Sep 15 Barber Daniel sold 25,000 shares Insider trading Form 4 President and CEO, about $120k, planned (10b5-1)
Sep 9 Korczynski Sherry sold 8,750 shares Insider trading Form 4 Chief Commercial Officer, about $46k, planned (10b5-1)
Aug 11 Results announcement Company filing 8-K

22 more events are on Measure

Free, no card, and it does not expire. See what the paid plans add

Risk factors, year on year

Item 1AMar 2026 10-KMar 2025

added: 78
dropped: 108
re-drafted: 50

Out of 262 passages in this year’s Item 1A.

New this year

2024 Underwritten Public Offering Capital raise of gross proceeds of $77,519, including partial exercise of the underwriters' option for $2,519

185 more passages are on Bespoke

Bespoke Create a free account

Free, no card, and it does not expire. See what the paid plans add